Antimalarial drug resistance, in particular resistance to Plasmodium falciparum, challenges
the treatment and control of malaria. In this Review, we summarise evolving patterns of …

Strategies to counteract or prevent emerging drug resistance are crucial for the design of
next-generation antimalarials. In the past, resistant parasites were generally identified …

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

Abstract Background In Uganda, artemether-lumefantrine is recommended for malaria
treatment and sulfadoxine-pyrimethamine for chemoprevention during pregnancy, but drug …

Antimalarial chemotherapy, globally reliant on artemisinin-based combination therapies
(ACTs), is threatened by the spread of drug resistance in Plasmodium falciparum parasites …

Emergence and spread of resistance in Plasmodium falciparum to the frontline treatment
artemisinin-based combination therapies (ACTs) in the epicenter of multidrug resistance of …

Artemisinin-based combination therapies (ACTs) have become the mainstay for malaria
treatment in almost all malaria endemic settings. Artemisinin derivatives are highly potent …

Artemisinin-based combination therapies (ACT) are currently used as a first-line malaria
therapy in endemic countries worldwide. This systematic review aims at presenting the …

We present case histories of four patients treated with artemether-lumefantrine for falciparum
malaria in UK hospitals in 2015 to 2016. Each subsequently presented with recurrent …

Background Treatment and control of malaria depends on artemisinin-based combination
therapies (ACTs) and is challenged by drug resistance, but thus far resistance to …